The study found that FCGR3A gene polymorphisms may correlate with response to frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R–CHOP) with diffuse large B-cell lymphoma (DLBCL) [20]. Here, FCGR3A is linked to diffuse large B-cell lymphoma.